Featured Updates
Press Releases.
Duo Oncology to Present Breakthrough DUO-207 Research at 2025 ASCO GI Conference.
Duo Oncology to Present Breakthrough DUO-207 Research at 2025 ASCO GI Conference.
Duo Oncology Awarded Prestigious NIH Grant to Advance Innovative Nanomedicine for Treatment of Pancreatic Cancer and Other Malignancies.
NIH STTR Award Funds Additional Studies Exploring Improved Duration of Treatment with DUO-207 in Mice and Dogs.
Duo Oncology Selected for Prestigious NCI SBIR Investor Initiatives Program
The National Cancer Institute has selected Duo Oncology for its elite Investor Initiative Program
Duo Oncology Nominated for Best Startup at 2024 Prix Galien USA Awards.
Galien Foundation, Dedicated to Innovation to Improve the Human Condition, Selects Duo Oncology as Nominee for Best Startup.
Duo Oncology Founders Publish in Advanced Science.
Drs. Song Li and Jingjing Sun, publish on novel ultrasmall precision nanomedicine.
Duo Oncology Awarded Grant from the NCI
The National Cancer Institute has Awarded Duo Oncology a Grant to Develop DUO-307
Duo Oncology Earns FDA Orphan Designation
Duo Oncology is pleased to announce that the Federal Drug Administration (FDA) has granted our lead product, ultrasmall nanomedicine DUO-207, Orphan Designation for the treatment of patients with pancreatic cancer.
Duo Oncology Founder Awarded NCI Grant
Dr. Song Li, founder of Duo Oncology, receives NCI award to develop chemo/immunotherapy nanomedicines.
Duo Oncology Founders Publish in Materials Today
Drs. Song Li and Jingjing Sun Publish in Materials Today on Novel Ultrasmall Nanomedicine Immunotherapy.
Report Cites Dr. Song Li’s Work in Nature Nanotechnology
Trade journal Genetic Engineering and Biotechnology News (GEN) has reported on the ongoing research of Duo Oncology Founder, Dr. Song Li.
Duo Oncology unveils new corporate logo
Duo Oncology unveils new corporate logo - Rebranded website highlights the company mission
Duo Oncology Completes Favorable PreIND Meeting
Favorable Written Option Confirms Clear Roadmap for DUO-207 Develop as First-Line Therapy for Pancreatic Cancer and Other Solid Malignancies.
Duo Oncology Signs Exclusive License with University of Pittsburgh
Duo Oncology Continues Development of Cancer Nanomedicine Platform and Products from Dr. Song Li of the Pitt Center for Pharmacogenetics
Duo Oncology Earns Orphan Designation
EMA Awards Lead Product DUO-207 Orphan Designation for Pancreatic Cancer
Duo Oncology Announces Key Leadership Team Addition
Dr. Katie Eichinger PharmD, PhD Joins Team as Director of Operations.
Duo Oncology to Hire Second Full Time Team Member
With manufacturing, non-clinical studies and regulatory filings all ongoing, Duo Oncology is expanding its full-time team.
Duo Oncology Announces Close of Initial Seed Investment
Duo Oncology is pleased to announce a $1M+ seed investment led by UPMC oncologists Dr. Stanley Marks and Dr. Jing-Zhou Hou.